Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy

NCT01487109 is registered in ClinicalTrials.gov with Concert Pharmaceuticals as lead sponsor.

NCT NCT01487109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01487109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy
Lead sponsor
Concert Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
January 31, 2015
Enrollment
170 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 2 diabetes mellitus